Search the Newsreel

Understanding Momentum Shifts in (PACS)

This article analyzes momentum shifts for Pacs Group Inc. (NASDAQ: PACS), highlighting weak near-term sentiment but long-term strength. It details institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis to guide investors on support and resistance levels.

Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) reported a Q2 loss of $0.31 per share, which was better than the Zacks Consensus Estimate of a $0.42 loss. However, the company missed revenue estimates, posting $5.15 million against an expected $5.43 million. Despite beating EPS estimates two out …

How TG Therapeutics’ Q2 2026 Revenue Surge And Higher Guidance At TG Therapeutics (TGTX) Has Changed Its Investment Story

FCBC|First Community Bankshares Inc|Price:49.520|Chg%:+0.200

Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker

An insider at Zevra Therapeutics (ZVRA) has filed a Form 144 notice to resell up to 42,666 common shares. These shares are linked to restricted stock units granted in June 2025 and are planned for potential sale on NASDAQ. The filing also references previous …

Home Bancshares director Jim Rankin sells $462,966 in HOMB stock

Jim Rankin, a director at Home Bancshares Inc. (NASDAQ:HOMB), sold 15,000 shares of company stock worth $462,966 on August 11, 2026. Following the sale, Rankin still holds over 209,000 shares of common stock and 6,000 restricted shares. This comes after Home Bancshares reported strong …

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat

ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal

What date does Scribe Therapeutics Inc.'s (SCTX) report Earnings - Earnings Calendar & Announcement

TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC

This article provides current stock price information for First Tracks Biotherapeutics, Inc. (TRAX) on MEXC, detailing its live price, market data, and recent performance. It also includes instructions on how to buy TRAX on MEXC and offers a company overview, including its focus on …

Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026

Iovance Biotherapeutics, Inc. stock has rallied over 130% in 2026, closing at $6.98, but is showing strong overbought signals across multiple timeframes with daily RSI at 73.02. While the daily trend remains bullish due to strong EMA alignment and positive MACD, the elevated RSI …

Iovance Biotherapeutics, Inc. stock jumps 130% in 2026 but RSI screams overbought

Will MYQORZO Traction Amid Weaker Q2 2026 Results Change Cytokinetics' (CYTK) Narrative

International Bancshares (IBOC) Could Be 91% Undervalued As Earnings And Dividend Draw Focus

TransMedics Group (TMDX) Is Up 5.6% After Raising 2026 Revenue Guidance Despite EPS Compression

General Dynamics director Peter Wall sells $788,897 in stock By Investing.com

General Dynamics director Peter Wall sold 1,990 shares of company stock for $788,897 after exercising stock options. This transaction occurred on August 10, 2026, with the stock trading near its 52-week high. Following the sale, Wall directly owns 3,969 shares of General Dynamics common …

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why

Diretor da General Dynamics vende ações no valor de US$ 788.897 - Investing.com Brasil

BofA Securities Maintains Aardvark Therapeutics(AARD.US) With Sell Rating

BofA Securities has reiterated its Sell rating on Aardvark Therapeutics (AARD.US). The article does not provide further details regarding the financial implications or the analyst's rationale for maintaining this rating.

Photronics, Inc. (PLAB) Investors: September 4, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman

Hagens Berman has initiated an investigation into Photronics, Inc. (PLAB) following a class action lawsuit alleging the company misled investors about the demand for its high-end integrated circuit (IC) photomask products. The lawsuit claims Photronics made false statements regarding robust global demand, while facing …

Corcept therapeutics chief development officer sells $1.8m in stock

William Guyer, Chief Development Officer at Corcept Therapeutics Inc. (NASDAQ:CORT), sold shares worth approximately $1.85 million on August 10, 2026, through two separate transactions under a 10b5-1 plan. Despite the sales, which occurred while the stock was near its 52-week high, Guyer also acquired …

Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?

Diluted earnings per share (diluted EPS) of Spero Therapeutics, Inc. – BMV:SPRO

XPO (XPO) Could Be 9% Undervalued After Freight Demand Recovery Gains Pace

XPO (XPO) is attracting investor attention due to a recovery in freight demand, growing shipments, and tonnage, coupled with tighter transport capacity. Despite a significant year-to-date share price return, Simply Wall St's analysis suggests XPO could be 9% undervalued with a fair value of …

Is Verisk Analytics' (VRSK) AI Subscription Momentum Reframing Its Valuation Narrative?

Verisk Analytics is gaining attention due to the increased adoption of its AI-enhanced platforms, XactAI and Core Lines Reimagine, which are driving subscription-based revenue. This growth highlights a tension between investor enthusiasm for AI-driven recurring revenue and concerns about the company's valuation and potential …

Relmada (RLMD) Q2 2026 Earnings Call Transcript

Amdocs - AOS - Stock Price & News

This article provides a comprehensive overview of Amdocs (AOS) stock, including its current price, market capitalization, and key financial metrics. It details the company's revenue and EPS growth over several fiscal years, along with quarterly performance and fundamental data. The article also includes general …

BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20

BMO Capital has initiated coverage on MapLight Therapeutics (MPLT.US) with a Buy rating and set a price target of $20. This indicates a positive outlook from the investment firm regarding the company's future stock performance.

Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock

Mittie Doyle, CMO at Avalo Therapeutics (NASDAQ:AVTX), sold 679 shares for $13,580 after exercising stock options under a Rule 10b5-1 trading plan. Following these transactions, she directly holds 51,776 shares and 114,413 stock options. This news follows Avalo's inclusion in the Russell 2000 and …

NTLA|Intellia Therapeutics Inc|Price:11.910|Chg%:+0.080

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

MacroGenics 2026: Revenue $32.83M, EPS $0.31— 10-Q Summary

MacroGenics reported strong Q2 2026 results with revenue of $32.83M and diluted EPS of $0.31, largely driven by a TZIELD milestone payment and increased ZYNYZ royalty income. The company achieved net income of $19.52M, a significant improvement from the prior year's loss, following the …

PTC Therapeutics Is Maintained at Overweight by Barclays

Barclays has reiterated its 'Overweight' rating on PTC Therapeutics (PTCT). The analyst firm maintained a price target of $70.00 for the company's stock. This indicates a positive outlook from Barclays regarding PTC Therapeutics' future performance.

Price-Driven Insight from (CPBI) for Rule-Based Strategy

This article provides a price-driven analysis of Central Plains Bancshares Inc. Com (NASDAQ: CPBI), indicating a near-term neutral sentiment amidst mid and long-term strength. It highlights compelling upside potential with no resistance levels above the current price and presents three institutional trading strategies tailored …

Nasdaq, S&P 500 Futures Edge Lower Ahead Of Fed Week, AI Earnings Test: Why POET, ATOM, OGN, QCOM, NTLA Are In Focus

Delek Logistics Partners, LP (DKL) Latest Stock News & Headlines